New meningitis B vaccines – does the best science matter?

LONDON, UK----20th November 2009----ExpertREACT. At the recent Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009), new vaccines to protect against *N.meningitidis* serogroup B were discussed. Both Wyeth and Novartis Vaccines are positioning their approaches on “the best science”. VacZine Analytics discuss the current issues.

In terms of current *meningococcal* disease burden, the statistics related to serogroup B are convincing when making arguments in support of new meningitis vaccines...........

CONTINUED......

***NOTE*** This article is available only on a “pay per view” basis or to individual existing VacZine Analytics clients who have purchased MarketVIEW: meningitis ACWY vaccines (US Version), CAT No: VAMV009, published December 2009.

Please visit [www.vaczine-analytics/products-expertreact](http://www.vaczine-analytics/products-expertreact)

References and Notes:


5) Islam et al., fHBP Variation and Expression is Independent of Age, Gender and Disease Outcome for Meningococcal Serogroup B Disease. Poster Presentation at Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009)

6) Findlow J., et al. Immunogenicity of an investigational recombinant meningococcal vaccine with and without outer membrane vesicles, against a serogroup B strain representative of the Normandy Outbreak. Poster Presentation at Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009)

A printable version of this article is available upon request.

VacZine Analytics® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics® and “the spiral logo” are UK Registered Trademarks, 2009

© 2009 VacZine Analytics. All rights reserved.